Pharma Clinical Trial Services: World Market 2013-2023
NEW YORK, March 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Report DetailsDiscover new trends, opportunities and prospects for contract clinical trials
What's the outlook for clinical research providers? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and commercial prospects.Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in clinical trial outsourcing, helping your research and analyses. Forecasts and other analyses to help you stay ahead in knowledge In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You receive 74 tables, 61 charts and two survey interviews. There's rising demand for that pharma research. The outsourced clinical trials market will increase its revenues from 2013 to 2023, achieving strong growth. Clinical research organisations (CROs) and their clients will benefit. The following sections show what you find in our new report. Discover prospects for the world market and submarkets Along with revenue prediction for the overall world market, you see forecasts to 2023 for eight submarkets:• Early phase clinical trial services• Late phase services. We also show forecasts for contract services by therapeutic area: • Cancers • Central nervous system (CNS) diseases • Cardiovascular diseases • Infections • Metabolic disorders • Other therapy areas (grouped prediction). You gain advantages by understanding trends, opportunities and challenges. Our investigation shows what will stimulate and restrain business for CROs. Our work also breaks the main world forecast into geographical markets.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV